1.. INTRODUCTION {#sec1}
================

Osteoporosis is a systemic skeletal disorder characterized by a decrease in bone strength leading to an increased risk of fracture. Osteoporosis can significantly reduce musculoskeletal function and leads to disability, even mortality ([@ref1]). Diabetes and osteoporosis are "covert" diseases, making the diagnosis is missed until the complications manifest. Type 2 diabetes mellitus is a risk factor for osteoporosis ([@ref2]). The relationship between these two diseases is complex and remains controversial ([@ref3]).

Diabetes decreases osteoclast activity and disrupts osteoblast activity of the bone cells, resulting in low bone turnover. This will inhibit osteoclasts and osteoblasts by inducing oxidative stress, hyperglycemia, and loss of weight ([@ref4], [@ref5]). Advanced glycation end-products will interfere with bone formation by suppressing the osteoblastic lineage ([@ref6]), apoptosis of osteoblast ([@ref7]), inhibition of osteoblast-specific factors and decreased mineralization in vitro ([@ref8]).

Management of osteoporosis in diabetes mellitus includes lifestyle interventions, optimization of lifestyle control, analysis of the impact of diabetes mellitus treatment on fracture risk, and treatment with anti-osteoporosis ([@ref9]). Until recently, to the knowledge of the researchers, herbal applications in the treatment of osteoporosis related to diabetes mellitus remain rare. An application of hesperidin to mice with type 1 diabetes mellitus can suppress some pro-inflammatory markers and increase serum markers of bone turnover, including osteopontin and osteocalcin, and lower alkaline phosphatase ([@ref10]). Green tea supplementation has not been able to improve bone mineral content and bone mass in individuals with diabetes mellitus ([@ref11]). Anhydroicaritin is a prenylated flavonoid found in several species of *Epimedium*. Anhydroicaritin is capable of suppressing osteoclast differentiation and improving bone loss in diabetic rats ([@ref12]).

The OPG/RANKL/RANK system plays an important role in bone remodeling. RANK is a receptor located on the surface of osteoclasts. RANK ligands are RANKL synthesized and secreted by bone marrow osteoblasts and stromal cells. RANKL activation of RANK will lead to differentiation of osteoclasts and bone resorption. OPG, functioning as the decoy receptor for RANKL, will block this activity ([@ref13], [@ref14]).

*Scurrula atropurpurea* is a plant that grows on tea trees, known as a parasite species for tea trees. Empirically, these plants have been used by Javanese people to cure cancers ([@ref15], [@ref16]). *Scurrula atropurpurea* triggers apoptosis in cervical cancer ([@ref17]). *Scurrula atropurpurea* also acts as an antioxidant. Some of the active components of this plant is the antioxidant quercctin, quercitrin and kaempferol ([@ref18]-[@ref22]). Exogenous antioxidant compounds may suppress oxidative stress that can further inhibit inflammation pathways ([@ref23]). Until recently, *Scurrula atropurpurea* potential for the treatment of osteoporosis related to diabetes mellitus has not been revealed. Specifically, the effects of *Scurrula atropurpurea* on the RANKL/RANK/OPG system has not been revealed, as well.

2.. AIM {#sec2}
=======

The purpose of the present study was to analyze the *in silico* interaction between the active compounds of *Scurrula atropurpurea* and the RANKL/RANK/OPG system.

3.. METHODS {#sec3}
===========

**Search for constituent amino acids of RANK, RANKL, and OPG**

The constituent amino acid sequences of RANK proteins (GI: 19924309), RANKL (GI: 2612922), and OPG (GI: 2072185) were obtained from the National Center for Biotechnology Information (NCBI) database, the United States National Library of Medicine (NLM), National Institute of Health (NIH) (<http://www.ncbi.nlm.nih.gov>). The 3D structure of RANK, RANKL, and OPG in the \*.sdf file format would be converted into \*.pdb file format using the OpenBabel software ([@ref24]).

**Search for the structure of the active components of *Scurrula atropurpurea***

The 3D structure of the constituent active compounds of *Scurrula atropurpurea* was obtained from the PubChem Open Chemistry Database. There were nine active compounds: aviculin (CID 10391477), caffeine (CID 2519), catechin (CID: 9064), epicatechin (CID: 72276), kaempferol (CID 5280863), quercetin (CID 5280343), quercitrin (CID 5280459), rutin (CID 5280805), and theobromine (CID 5429). The 3D structure of those various compounds in the \*.sdf file format will be converted into \*.pdb file format using the OpenBabel software ([@ref24]).

**3D modeling of protein structure**

The 3D structure of the target proteins was predicted by using the SWISS-MODEL web server by means of the homology modeling method. Those 3D protein structures were subsequently validated using the Ramachandran plot analysis ([@ref25], [@ref26]).

**Protein-ligand docking and visualization**

Docking of the active compounds of *Scurrula atropurpurea* with the target proteins was simulated using the HEX 8.0 software ([@ref27]). The docking protocol consisted of three visualization stages: minimization of rigid-body energy, semi-flexible repairs, and finishing refinements in explicit solvents. Results of the docking were then visualized using the Chimera 1.6.2 and Discovery Studio 4.1 software.

**Analysis of protein-ligand bond interactions**

Results of the docking analysis would subsequently be visualized using the Discovery Studio 4.1, LigPlot+ and LigandScout 3.1 software ([@ref28], [@ref29]). Analysis of protein-ligand bond interactions was performed to determine the number and type of bonds formed, such as hydrogen bonds, hydrophobic bonds, and van der Waals bonds.

4.. RESULTS {#sec4}
===========

**Interaction of RANKL with the active compounds of *Scurrula atropurpurea***

Table 1 shows the interaction energy between the various active compounds of *Scurrula atropurpurea* with RANKL. Sequentially, those bond energies were RANKL-aviculin (-274.96 kJ/mol), RANKL-rutin (-263.12 kJ/mol), RANKL-quercitrin (--256.98 kJ/mol), RANKL-quercetin (--226.50 kJ/mol), RANKL-kaempferol (--221.65 kJ/mol), RANKL-catechin (-214.85 kJ/mol), RANKL-epicatechin (-211.66 kJ/mol), RANKL-caffeine (-171.73 kJ/mol) and RANKL-theobromine (-161.14 kJ/mol). Molecular docking between nine active compounds of *Scurrula atropurpurea* against the structure of RANKL can be seen in [Figure 1](#fig1){ref-type="fig"}.

**Interaction of RANK with the active compounds of *Scurrula atropurpurea***

RANK interaction with the active compounds of *Scurrula atropurpurea* is shown in Table 2. Sequentially, the bond energies were RANK-rutin (-719.26 kJ/mol), RANK-catechin (-680.15 kJ/mol), RANK-caffeine (-654.48 kJ/mol), RANK-theobromine (-651.77 kJ/mol), RANK-quercitrin (-650.6 8 kJ/mol), RANK-kaempferol (-643.03 kJ/mol), RANK-epicatechin (-641.86 kJ/mol), RANK-quercetin (-641.76 kJ/mol), and RANK-quercetin (-641.76 kJ/mol) and RANK-aviculin (-628.62 kJ/mol).

**Interaction OPG with the active compounds of *Scurrula atropurpurea***

Table 3 shows the interaction energy between the active compounds of *Scurrula atropurpurea* and OPG. Sequentially, the bond energies were OPG-epicatechin (-590.09 kJ/mol), OPG-theobromine (-578. 08 kJ/mol), OPG-caffeine (-568. 88 kJ/mol), RANKL-catechin (-560. 63 kJ/mol), OPG-quercitrin (-554.50 kJ/mol), OPG-rutin (-547.91 kJ/mol), OPG-quercetin (-545. 75 kJ/mol), OPG-kaempferol (-544. 48 kJ/mol), and OPG-aviculin (-539. 15 kJ/mol).

5.. DISCUSSION {#sec5}
==============

RANKL is expressed in various tissues, including skeletal muscles, thymus, liver, colon, small intestine, adrenal glands, osteoblasts, epithelial cells of the mammary gland, prostate, and pancreas ([@ref30]). For the first model, we simulated the changes in energy interactions between nine active ingredients with RANKL relative to the interaction between RANK and RANKL. In the present study, energy interaction between the nine active compounds of *Scurrula atropurpurea* and RANKL was greater than that of between RANK and RANKL (-660.95 kJ/mol). This indicates that the bonding of RANK to RANKL is easier than that of the nine active compounds of *Scurrula atropurpurea* to RANKL. In other words, the nine active compounds of *Scurrula atropurpurea* are not easy to form a complex with RANKL. The authors hypothesized that the nine active ingredients of *Scurrula atropurpurea* would not interfere with the physiological function of RANKL. Physiologically, RANKL can activate osteoclasts to regulate the recruitment of progenitor cells for homeostasis and host defense ([@ref31]).

For the second model, we simulated the energy changes in the interaction of RANK with the nine active ingredients and the bonding to RANKL. Of those nine active compounds, only the RANK-routine (-719.26 kJ/mol) and RANK-catechin (-680.15 kJ/mol) complexes had less interaction energy than that of RANK-RANKL (- 660.95 kJ/mol). Thus, the initial interaction of RANK with catechin or rutin will facilitate the bond of RANK to RANKL. This is in contrast to previous findings that rutin decreases the activity of RANKL ([@ref32], [@ref33]). In the present study, the initial interaction of RANK with caffeine, theobromine, quercitrin, kaempferol, epicatechin, quercetin, and aviculin, followed by interaction with RANKL, has greater interaction energy than the direct interaction of RANK with RANKL. This indicates that caffeine, theobromine, quercitrin, kaempferol, epicatechin, quercetin and aviculin can act as inhibitors of osteoclast activation. Previous studies have shown that quercetin and kaempferol reduce RANKL-induced osteoclast differentiation ([@ref34], [@ref35]). Quercitrin suppresses RANKL mRNA expression in osteoblasts and inhibits osteoclast production ([@ref36]).

In the third model, we simulated the changes in the interaction energy of OPG bond to RANKL relative to OPG bond to the nine active ingredients followed by its interaction with RANKL. The interaction of RANKL with OPG has an interaction energy of -584.74 kJ/mol. Of the nine active ingredients *Scurrula atropurpurea*, only epicatechin would facilitate its interaction with RANKL (-590.09 kJ/mol) when forming a complex with OPG. Meanwhile, eight compounds had energy interactions greater than those of OPG and RANKL. The present study extends previous findings that epicatechin can inhibit RANKL-related osteoclastogenesis by suppressing NF-kB signals ([@ref37]).

![The interaction between amino acids in the RANKL structure with nine active ingredients of Scurrula atropurpurea.](AIM-27-8-g001){#fig1}

6.. CONCLUSION {#sec6}
==============

The nine active ingredients of *Scurrula atropurpurea* do not interfere with the physiological function of RANKL to interact with RANK. The initial interaction of RANK with catechin or rutin will facilitate the bond of RANK to RANKL. Epicatechin will facilitate its interaction with RANKL when forming a complex with OPG.
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